| 产品描述: | BAY-1797 是一种高效、具有口服活性的,选择性的 P2X4 拮抗剂,对人 P2X4 的 IC50 为 211 nM。BAY-1797 在其它 P2X 离子通道上没有或表现出很弱的活性。BAY-1797 具有抗伤害和抗炎作用。 |
| 靶点: |
IC50: 211 nM (human P2X4), >50 μM (human P2X1), >30 μM (human P2X23), 8.3 μM (human P2X3), 10.6 μM (human P2X7).;P2XReceptor |
| 体外研究: |
BAY-1797 inhibits human, mouse, and rat P2X4 in 1321N1 cells with IC50s of 108 nM, 112 nM, and 233 nM, respectively. BAY-1797 exerts no measurable activity on hERG and carbonic anhydrase II (both IC50>10 μM). BAY-1797 is also tested against a panel of off-targets, including G-protein coupled receptors (GPCRs), ion channels, kinases, and transporters at 10 μM. An inhibitory activity against the dopamine transporter (DAT, IC50 2.17 μM) was revealed as the only hit. |
| 体内研究: |
BAY-1797 (12.5-50 mg/kg; p.o.) shows a significant induction of PGE2 levels in the inflamed paw in the mouse Complete Freund’s Adjuvant (CFA) inflammatory pain model. BAY-1797 (50 mg/kg; once daily for multiple p.o. administrations) induces a significant reduction of the ipsilateral paw load 24 and 48 h after CFA injection. |
| 参考文献: |
1. Werner S, et al. Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile. J Med Chem. 2019 Dec 26;62 |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.399 ml |
11.994 ml |
23.988 ml |
| 5 mM |
0.48 ml |
2.399 ml |
4.798 ml |
| 10 mM |
0.24 ml |
1.199 ml |
2.399 ml |
| 50 mM |
0.048 ml |
0.24 ml |
0.48 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |